| 31.12.2009 | 30.9.2009 | ||
| |
|||
| Net assets (CHF 000) |
674,420 | 695,222 | |
 | |||
| Cash |
130,546 | 184,745 | |
| |||
| Disbursed |
648,036 |
656,125 | |
| |||
| Investments in private companies |
465,001 | 449,210 | |
| |||
| Net asset value (NAV) per share (CHF) |
66.58 | 67.30 | |
| |||
| Share price (CHF) |
47.95 | 46.85 | |
| |||
| Performance of net assets (NAV) | |||
| In the quarter 1.10. - 31.12.2009 | -1% |
||
| In the 9-month period 1.4. - 31.12.2009 | 13% |
||
| Since start of business (12.7.2001) | -33% |
||
| |||
| Performance of relevant market indices (in CHF) | |||
| NBI - Nasdaq Biotech Index (since 12.7.2001) | -43% | ||
| |||
| MSCI World Pharma Index (since 12.7.2001) | -45% | ||
| |||
| Number of shares issued (registered shares) |
10,700,000 |
11,262,859 | |
| |||
| Number of shares outstanding (registered shares) |
10,129,976 | 10,329,531 | |
| |||
| Number of registered shareholders |
1,327 | 1,418 | |
| |||
Key Figures as at 31.12.2009
News
Financial Reports
Key Figures
| as at 28.02.2010 |
CHF |
| NAV per share | 68.38 |
| Net assets | 693 Mio. |
Search
News Registration